Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro

CD19 directed chimeric antigen receptor T cell (CART19) therapy has shown remarkable activity in B cell lymphoma and acute lymphoblastic leukemia (ALL). With the emergence of therapeutic anti CD19 antibodies for the treatment of B cell malignancies, it remains to be elucidated whether such antibodies would interfere with the ability of CART19 to exert their antitumor effect in a subsequent therapy.Tafasitamab is an Fc enhanced humanized anti CD19 monoclonal antibody which mediates antibody dependent cellular toxicity (ADCC), antibody dependent cellular phagocytosis and direct cytotoxicity.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Paulina Horvei, Reona Sakemura, Michelle J. Cox, Claudia Manriquez Roman, Kendall J. Schick, Michael W. Ruff, Mehrdad Hefazi, Erin E. Tapper, Michael J. Hansen, J ürgen Schanzer, Jan Endell, Neil E. Kay, Grzegorz S. Nowakowski, Saad S. Kenderian Tags: 332 Source Type: research